Effects of a combination of olive leaf extract and potassium on blood pressure in participants with mild to moderate hypertension: A double blind, randomized, placebo-controlled trial
Phytomedicine · 2026
DOI: 10.1016/j.phymed.2026.158138 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Phytomedicine, 2026. Verfasst von Johannes-Paul Fladerer-Grollitsch und 5 weiteren Autor:innen. Beteiligte Einrichtung: Karl-Franzens-Universität Graz, Beethovenstraße 8, 8010 Graz, AT; Apomedica Pharmazeutische Produkte GmbH, Roseggerkai 3, 8010 Graz, AT. Electronic a…. Hauptthemen laut MEDLINE: Antihypertensive Agents, Blood Pressure, Hypertension, Olea. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Graz.
Abstract (Originalsprache)
BACKGROUND: Hypertension is a key modifiable driver of cardiovascular risk and often clusters with dyslipidemia and insulin resistance within the metabolic syndrome. Olive leaf extract (OLE) and potassium have traditionally been used to support blood pressure (BP) management and cardiometabolic health. PURPOSE: To investigate the effect of this OLE - potassium combination on BP and key cardiometabolic markers. STUDY DESIGN: In this randomized, double-blind, placebo-controlled study, 70 adults with untreated mildly to moderately elevated BP received an OLE - potassium supplement (1000 mg OLE, ≥160 mg oleuropein, 300 mg potassium/day) or placebo for 12 weeks. RESULTS: While office BP fell significantly over time in both groups, 7-day home-based BP monitoring showed a significant greater response, with morning systolic BP decreasing by 5.4 mmHg, in the verum group. Supplementation also reduced total cholesterol by 11.1 mg/dL, LDL-cholesterol by 6.9 mg/dL, and triglycerides by approximately 22 mg/dL at Week 6, while HDL-cholesterol remained stable. Fasting glucose and HbA1c were unchanged, but fasting insulin and HOMA-Index declined in the verum group, indicating a modest improvement in insulin sensitivity. Additionally, oxidized LDL decreased by ∼23 %, without changes in hs-CRP. Quality-of-life scores remained stable, although global self-ratings favoured the combination. The intervention was well tolerated, with no product-related serious adverse events. CONCLUSION: The combination of OLE and potassium is a safe adjunctive strategy for individuals with mildly to moderately elevated BP, with favourable effects on lipid profile, oxidative status, and insulin sensitivity that may help reduce cardiometabolic risk in the context of metabolic syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Karl-Franzens-Universität Graz, Beethovenstraße 8, 8010 Graz, AT; Apomedica Pharmazeutische Produkte GmbH, Roseggerkai 3, 8010 Graz, AT. Electronic address: johannes.fladerer@uni-graz.at.
- Karl-Franzens-Universität Graz, Beethovenstraße 8, 8010 Graz, AT.
- Apomedica Pharmazeutische Produkte GmbH, Roseggerkai 3, 8010 Graz, AT.
- BioTeSys GmbH, Schelztorstraße 54-56, 73728 Essingen, DE.
Förderung
- University of Graz
Zitieren
APA
Fladerer-Grollitsch, J. P., Bucar, F., Klein, T., Kompek, A., Menzel, D., & Schön, C. (2026). Effects of a combination of olive leaf extract and potassium on blood pressure in participants with mild to moderate hypertension: A double blind, randomized, placebo-controlled trial. Phytomedicine. https://doi.org/10.1016/j.phymed.2026.158138
Vancouver
Fladerer-Grollitsch JP, Bucar F, Klein T, Kompek A, Menzel D, Schön C. Effects of a combination of olive leaf extract and potassium on blood pressure in participants with mild to moderate hypertension: A double blind, randomized, placebo-controlled trial. Phytomedicine. 2026. doi:10.1016/j.phymed.2026.158138
BibTeX
@article{FladererGrollitsch2026,
author = {Fladerer-Grollitsch, Johannes-Paul and Bucar, Franz and Klein, Thomas and Kompek, Albert and Menzel, Daniel and Schön, Christiane},
title = {Effects of a combination of olive leaf extract and potassium on blood pressure in participants with mild to moderate hypertension: A double blind, randomized, placebo-controlled trial},
journal = {Phytomedicine},
year = {2026},
doi = {10.1016/j.phymed.2026.158138}
}
EUVIMED